Novartis loses out on Glivec case

Novartis loses out on Glivec case
Time for a leap
No second chance?
‘Regulations don’t differ, inspections do’
Formation of a new federation
Quarter of the Rupee
Elder steps into the regulated markets
GlaxoSmithKline divests its fine chemicals business
TCG partners with US-based Constella
Aventis, Themis release diabetes FDC
Waters MassLynx Software to feature multivariate statistical tools
Brainwave Biosolutions launches Gene Minerva